Evidence map›Paper›PMID 37744308›Full record

ArticleJTO clinical and research reports2023

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With

Sally C M Lau, Kirstin Perdrizet, Andrea S Fung, Danilo Giffoni M M Mata, Jessica Weiss, Nick Holzapfel, Geoffrey Liu, Penelope A Bradbury, Frances A Shepherd, Adrian G Sacher and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sally C M LauDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Kirstin PerdrizetWilliam Osler Health System, Brampton Civic Hospital, Brampton Ontario, Canada.
Andrea S FungDepartment of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
Danilo Giffoni M M MataDepartment of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Jessica WeissDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Nick HolzapfelDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Geoffrey LiuDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Penelope A BradburyDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Frances A ShepherdDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Adrian G SacherDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Harriet FeilotterDepartment of Pathology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
Brandon SheffieldWilliam Osler Health System, Brampton Civic Hospital, Brampton Ontario, Canada.
David HwangDepartment of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Ming Sound TsaoDepartment of Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Susanna ChengDepartment of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
Parneet CheemaWilliam Osler Health System, Brampton Civic Hospital, Brampton Ontario, Canada.
Natasha B LeighlDepartment of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: NSCLC with Methods: We reviewed all NSCLC cases with Results: Among 64 patients with Conclusions: Many patients with advanced

Indexed as

MET exon 14 skippingMET inhibitorsNSCLCPD1 inhibitors

Identifiers

PMID37744308
PMCPMC10514105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.